Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews · Urology

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 4 · 57.1%Moderate 3 · 42.9%High 0 · 0%

Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) vs ADT only

Death (all causes)

Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) probably leads to lower time to death due to any cause (absolute effect size estimates based… compared with ADT only (moderate certainty).

1 finding from 1 review

Taxane‐based chemohormonal therapy for metastatic hormone‐sensitive prostate cancer 2018 · Cochrane Headline outcomes only
HR 0.77 [0.68, 0.87]
3 studies · 2261 participants
Moderate

Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) vs ADT only

Adverse events grade 3 to 5 Range of

Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) may leads to higher grade III to V adverse events compared with ADT only (low certainty).

1 finding from 1 review

Taxane‐based chemohormonal therapy for metastatic hormone‐sensitive prostate cancer 2018 · Cochrane Headline outcomes only
RR 2.98 [2.19, 4.04]
1 study · 375 participants
Low

Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) vs ADT only

Prostate cancer‐specific death5

Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) probably leads to lower prostate cancer‐specific death5 compared with ADT only (moderate certainty).

1 finding from 1 review

Taxane‐based chemohormonal therapy for metastatic hormone‐sensitive prostate cancer 2018 · Cochrane Headline outcomes only
RR 0.79 [0.7, 0.89]
3 studies · 2261 participants
Moderate

Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) vs ADT only

Time to progression

Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) probably leads to lower time to progression (absolute effect size estimates based on… compared with ADT only (moderate certainty).

1 finding from 1 review

Taxane‐based chemohormonal therapy for metastatic hormone‐sensitive prostate cancer 2018 · Cochrane Headline outcomes only
HR 0.63 [0.56, 0.71]
3 studies · 2261 participants
Moderate

Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) vs ADT only

Withdrawals due to adverse events

Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) may leads to higher discontinuation due to adverse events compared with ADT only (low certainty).

1 finding from 1 review

Taxane‐based chemohormonal therapy for metastatic hormone‐sensitive prostate cancer 2018 · Cochrane Headline outcomes only
RR 79.41 [4.92, 1282.78]
1 study · 385 participants
Low

Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) vs ADT only

All adverse events

Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) may leads to higher all adverse events compared with ADT only (low certainty).

1 finding from 1 review

Taxane‐based chemohormonal therapy for metastatic hormone‐sensitive prostate cancer 2018 · Cochrane Headline outcomes only
RR 1.11 [1.06, 1.17]
1 study · 375 participants
Low

Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) vs ADT only

Quality of life at 12 months (

1 finding from 1 review

Taxane‐based chemohormonal therapy for metastatic hormone‐sensitive prostate cancer 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 790 participants
Low